{
    "nctId": "NCT00301925",
    "briefTitle": "Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery",
    "officialTitle": "Trial of Accelerated Adjuvant Chemotherapy With Capecitabine in Early Breast Cancer (TACT2)",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 4400,
    "primaryOutcomeMeasure": "Disease-free survival (DFS) at 5 years",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histological diagnosis of invasive breast carcinoma\n\n  * Cytological proof of malignancy alone is not sufficient\n  * Early stage disease (T0-3, N0-2, M0) without clinical suspicion or evidence of distant metastases on routine staging\n  * No locally advanced breast cancer (T4 and/or N3 disease)\n* Completely resected disease by breast-conserving surgery with axillary node clearance or modified radical mastectomy within the past 4-8 weeks\n\n  * Negative surgical margins required, unless either of the following are true:\n\n    * Deep surgical margins after full thickness resection\n    * Noninvasive cancer at surgical margins for which a mastectomy is planned after completion of study chemotherapy\n  * No contraindication for or refusal of postoperative radiotherapy in patients who underwent prior breast-conserving surgery\n* Definite indication for adjuvant chemotherapy\n* No prior or current invasive breast cancer or bilateral breast cancer\n\n  * Prior surgically-treated ductal carcinoma in situ or lobular carcinoma in situ allowed\n* Hormone receptor status:\n\n  * Estrogen receptor- and/or progesterone receptor-positive or -negative tumor\n\nPATIENT CHARACTERISTICS:\n\n* Sex: male or female\n* Menopausal status: premenopausal or postmenopausal\n* No previous malignancy except basal cell carcinoma, carcinoma in situ of the cervix, or any cancer from which the patient has been disease-free for 10 years and for which treatment consisted solely of resection\n* ECOG status 0 or 1\n* Hemoglobin \\> 9 g/dL\n* WBC \\> 3,000/mm\u00b3\n* Platelet count \\> 10,000/mm\u00b3\n* Bilirubin normal (unless due to known Gilbert's disease)\n* AST and ALT \u2264 1.5 times upper limit of normal (ULN)\n* Albumin normal\n* Creatinine \u2264 1.5 times ULN\n* Creatinine clearance \\> 50 mL/min\n* No active, uncontrolled infection\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n* No concurrent medical, psychiatric, or geographic problems that might prevent completion of treatment or follow-up\n* Available for a minimum of 5 years' follow-up\n* No known serious viral infection such as active hepatitis B, hepatitis C, or HIV\n* No significant cardiac disease, such as impaired left ventricular function or active angina requiring regular anti-anginal medication and/or resulting in restricted physical activity\n* No history of significant renal impairment or disease\n\nPRIOR CONCURRENT THERAPY:\n\n* No simultaneous participation in the active intervention phase of another treatment trial\n* Not being approached or recruited for another trial within 2 months of study entry\n* No previous chemotherapy, hormonal therapy or radiotherapy for the treatment of pre-invasive or invasive cancer except for either of the following:\n\n  * Previous radiotherapy for basal cell carcinoma\n  * Previous preoperative endocrine therapy, provided there was no evidence of progression during this therapy, it lasted for less than 6 weeks in duration, and it was stopped at least one month prior to trial entry\n* Concurrent luteinizing hormone-releasing hormone analog therapy allowed for premenopausal patients\n* More than 4 weeks since prior hormone replacement therapy (HRT) or pre-operative endocrine therapy\n* No prior breast conserving surgery if there is a contradiction for or refusal of postoperative radiotherapy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}